Diversity in Clinical Trials: A New Perspective Based on FDA Requirements and Translation
Unlock Valuable Insights into Inclusive Research and Ethical Global Engagement
We gathered those passionate about advancing healthcare through diverse and inclusive clinical trials. Our recorded webinar is designed to provide you with a fresh perspective on diversity in clinical trials aligned with the latest FDA requirements and translation practices.
What should you expect from our one-hour presentation:
- Insights on FDA Requirements: Gain a comprehensive understanding of the latest FDA guidelines and requirements pertaining to diversity in clinical trials. Stay ahead of the curve and ensure your research meets the highest regulatory standards.
- Translation Best Practices: Explore the crucial role of translation in ensuring ethical and effective communication with diverse participant groups. Learn how precise translation can enhance informed consent and contribute to the success of your trials.
- Real-world Case Studies: Understand the state of enrollment for clinical trials and diverse populations.
- Unlock the possibilities within emerging markets, encompassing more than 50% of the global population, and the potential for increased diagnoses, innovative treatments, and market expansion benefitting patients across diverse regions while simultaneously paving the way for new opportunities in both emerging and developed markets.
- Expert Speakers: Engage with industry experts Sara Tylosky, CEO of Farmacon Global and Anna Eisenberg, Director of Business Development for Morningside, A Questel company, as they share their insights, experiences, and practical tips for implementing diversity and translation strategies in clinical research.
Don’t miss this opportunity to revolutionize your approach to clinical trials, ensuring they are not only compliant but also genuinely inclusive. Embrace diversity, meet FDA requirements, and elevate your research to new heights!
Download Today!
About the Speaker:
Sara Tylosky, MBA, serves as the CEO at Farmacon Global, bringing over 20 years of experience leading teams in both large and small pharmaceutical environments. In her seven years as CEO, she has led Farmacon Global, a strategic CRO of medical consultants, in accelerating clinical trials, increasing diversity, supporting enrollment, and paving the way to market access in emerging markets.
Known for her high cultural intelligence and problem-solving skills, Sara and her team specialize in Rare Diseases, Immunology, Infectious Diseases, Cancer, and Vaccines. Fluent in Spanish and having lived on four continents, she has a particular focus on Latin America while actively expanding into other key markets globally. Sara’s direction plays a pivotal role in steering Farmacon Global toward healthcare innovation and global market leadership.
